Key result
Serum multi-protein biomarker profiles combined with clinical factors outperformed clinical features alone in predicting severe versus mild/moderate MS disability.
Why the study?
Few studies had examined blood biomarkers informative of patient-reported outcomes of disability in people with multiple sclerosis.
Do serum multi-protein biomarker profiles improve the prediction of patient-reported MS disability compared to clinical profiles alone?
Cross-Sectional (n=431)
Yes
Do serum multi-protein biomarker profiles improve the prediction of patient-reported MS disability compared to clinical profiles alone?
Serum multi-protein biomarker profiles combined with clinical factors improve the prediction of real-world MS disability status beyond clinical profiles alone.
Answers are grounded in this paper and cite their sources.
May improve MS disability prediction models; hypothesis-generating and requires prospective validation before clinical adoption.
Few studies examined blood biomarkers informative of patient-reported outcome (PRO) of disability in people with multiple sclerosis (MS). We examined the associations between serum multi-protein biomarker profiles and patient-reported MS disability. In this cross-sectional study (2017–2020), adults with diagnosis of MS (or precursors) from two independent clinic-based cohorts were divided into a training and test set. For predictors, we examined seven clinical factors (age at sample collection, sex, race/ethnicity, disease subtype, disease duration, disease-modifying therapy [DMT], and time interval between sample collection and closest PRO assessment) and 19 serum protein biomarkers potentially associated with MS disease activity endpoints identified from prior studies. We trained machine learning (ML) models (Least Absolute Shrinkage and Selection Operator regression [LASSO], Random Forest, Extreme Gradient Boosting, Support Vector Machines, stacking ensemble learning, and stacking classification) for predicting Patient Determined Disease Steps (PDDS) score as the primary endpoint and reported model performance using the held-out test set. The study included 431 participants (mean age 49 years, 81% women, 94% non-Hispanic White). For binary PDDS score, combined feature input of routine clinical factors and the 19 proteins consistently outperformed base models (comprising clinical features alone or clinical features plus one single protein at a time) in predicting severe (PDDS ≥ 4) versus mild/moderate (PDDS < 4) disability across multiple machine learning approaches, with LASSO achieving the best area under the curve (AUCPDDS = 0.91) and other metrics. For ordinal PDDS score, LASSO model comprising combined clinical factors and 19 proteins as feature input (R2PDDS = 0.31) again outperformed base models. The two best-performing LASSO models (i.e., binary and ordinal PDDS score) shared six clinical features (age, sex, race/ethnicity, disease subtype, disease duration, DMT efficacy) and nine proteins (cluster of differentiation 6, CUB-domain-containing protein 1, contactin-2, interleukin-12 subunit-beta, neurofilament light chain [NfL], protogenin, serpin family A member 9, tumor necrosis factor superfamily member 13B, versican). By comparison, LASSO models with clinical features plus one single protein at a time as feature input did not select either NfL or glial fibrillary acidic protein (GFAP) as a final feature. Forcing either NfL or GFAP as a single protein feature into models did not improve performance beyond clinical features alone. Stacking classification model using five functional pathways to represent multiple proteins as meta-features implicated those involved in neuroaxonal integrity as significant contributors to predictive performance. Thus, serum multi-protein biomarker profiles improve the prediction of real-world MS disability status beyond clinical profile alone or clinical profile plus single protein biomarker, reaching clinically actionable performance.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) conducted a cross-sectional in Multiple sclerosis (n=431). Serum multi-protein biomarker profiles combined with clinical factors vs. Clinical features alone or clinical features plus one single protein was evaluated on Patient Determined Disease Steps (PDDS) score (AUC 0.91). Serum multi-protein biomarker profiles combined with clinical factors outperformed clinical features alone in predicting severe versus mild/moderate MS disability.
Synapse has enriched 10 related papers. Consider them for comparative context: